Clinical Trials Directory

Trials / Completed

CompletedNCT03257930

Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
1 (actual)
Sponsor
hassan harby mohamed · Academic / Other
Sex
All
Age
15 Years – 60 Years
Healthy volunteers
Accepted

Summary

Use of ethanol injection in treatment of cystic thyroid nodule

Detailed description

Thyroid nodules are common discreet lesions in the parenchyma of thyroid gland which can either be palpated or made out during imaging like ultrasonography (USG).Clinically palpable thyroid nodules have a prevalence of 4-7% in the general population . However, the prevalence increases to 20-76% when USG is used for detection. Goiter and the associated thyroid nodules result in anxiety, cosmetic disfigurement, and rarely compressive symptoms necessitating surgical removal, a procedure inherently associated with risks and complications Percutaneous sclerotherapy has been suggested to be an effective alternative, especially in patients with cystic nodules. Simple cystic (purely cystic) constitutes 6-28% of all thyroid nodules, are usually benign, filled with cellular debris or blood, and are a result of degeneration or hemorrhage into a hyperplastic nodule. Among the various compounds (sodium tetradocyl sulfate, hydroxypolyethoxydodecan, tetracycline, and ethanol) tried for sclerosis of cystic thyroid nodules, outcomes are best and most studied with ethanol. However, data on outcomes of percutaneous aspiration and ethanol injection (PEI) in resolution of thyroid nodules is highly variable in different studies (success rate: 38-85%), which may be due to different populations studied and the heterogeneous nature of thyroid nodules evaluated.

Conditions

Interventions

TypeNameDescription
DRUGethanol injectioninject ethanol in cystic thyroid nodule and follow up until complete recovery

Timeline

Start date
2017-08-11
Primary completion
2018-07-11
Completion
2019-01-01
First posted
2017-08-22
Last updated
2020-05-15

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03257930. Inclusion in this directory is not an endorsement.